inolimomab
PreclinicalMonoclonal antibody
inolimomab is one of 39 biologic programs targeting Acute Graft Versus Host Disease. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
54 competitors in Acute Graft Versus Host Disease
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsPhase 3
Entyvio
TakedaPhase 3
Enbrel
IImmunex
Phase 3
8-Mop
TTherakos, Inc., a Mallinckrodt Company
Phase 3
Medrol
PfizerPhase 2
Cellcept
RochePhase 2
Nipent
PfizerPhase 2
Epidiolex
Jazz PharmaceuticalsPhase 2
Neoral
NovartisPhase 2
Rapamune
PPrism Pharmaceuticals
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for inolimomab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Preclinical[1]
- Company
- EElsaLys Biotech